Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Ave, Kelvin Grove, QLD 4059, Australia.
Int J Cancer. 2012 Sep 1;131(5):E614-24. doi: 10.1002/ijc.27392. Epub 2012 Jan 11.
Overexpression of the receptor tyrosine kinase EphB4 is common in epithelial cancers and linked to tumor progression by promoting angiogenesis, increasing survival and facilitating invasion and migration. However, other studies have reported loss of EphB4 suggesting a tumor suppressor function in some cancers. These opposing roles may be regulated by (i) the presence of the primary ligand ephrin-B2 that regulates pathways involved in tumor suppression or (ii) the absence of ephrin-B2 that allows EphB4 signaling via ligand-independent pathways that contribute to tumor promotion. To explore this theory, EphB4 was overexpressed in the prostate cancer cell line 22Rv1 and the mammary epithelial cell line MCF-10A. Overexpressed EphB4 localized to lipid-rich regions of the plasma membrane and confirmed to be ligand-responsive as demonstrated by increased phosphorylation of ERK1/2 and internalization. EphB4 overexpressing cells demonstrated enhanced anchorage-independent growth, migration and invasion, all characteristics associated with an aggressive phenotype, and therefore supporting the hypothesis that overexpressed EphB4 facilitates tumor promotion. Importantly, these effects were reversed in the presence of ephrin-B2 which led to a reduction in EphB4 protein levels, demonstrating that ligand-dependent signaling is tumor suppressive. Furthermore, extended ligand stimulation caused a significant decrease in proliferation that correlated with a rise in caspase-3/7 and -8 activities. Together, these results demonstrate that overexpression of EphB4 confers a transformed phenotype in the case of MCF-10A cells and an increased metastatic phenotype in the case of 22Rv1 cancer cells and that both phenotypes can be restrained by stimulation with ephrin-B2, in part by reducing EphB4 levels.
EphB4 受体酪氨酸激酶的过表达在上皮性肿瘤中很常见,通过促进血管生成、增加存活、促进侵袭和迁移来促进肿瘤进展。然而,其他研究报道 EphB4 的缺失表明其在某些癌症中具有肿瘤抑制功能。这些相反的作用可能受到以下因素的调节:(i)主要配体 Ephrin-B2 的存在,其调节肿瘤抑制相关途径;或(ii)Ephrin-B2 的缺失,其允许 EphB4 通过配体非依赖性途径进行信号转导,从而促进肿瘤发生。为了探索这一理论,我们在前列腺癌细胞系 22Rv1 和乳腺上皮细胞系 MCF-10A 中过表达 EphB4。过表达的 EphB4 定位于质膜富含脂质的区域,并通过 ERK1/2 的磷酸化和内化增加证实为配体反应性。EphB4 过表达细胞表现出增强的无锚定依赖性生长、迁移和侵袭,所有这些特征都与侵袭性表型相关,因此支持 EphB4 过表达促进肿瘤发生的假说。重要的是,在 Ephrin-B2 存在的情况下,这些作用被逆转,导致 EphB4 蛋白水平降低,表明配体依赖性信号转导具有肿瘤抑制作用。此外,延长配体刺激导致增殖显著减少,这与 caspase-3/7 和 -8 活性的升高相关。总之,这些结果表明,在 MCF-10A 细胞中,EphB4 的过表达赋予转化表型,在 22Rv1 癌细胞中赋予增加的转移性表型,并且两种表型都可以通过 Ephrin-B2 的刺激来抑制,部分原因是 EphB4 水平降低。